Published by the Commonwealth of Australia

**GOVERNMENT NOTICES** 

## **COMMONWEALTH OF AUSTRALIA**

## **Department of Health**

Therapeutic Goods Administration

## THERAPEUTIC GOODS ACT 1989

## DESIGNATION OF ICATIBANT (FIRAZYR) AS AN ORPHAN DRUG

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 ("the Regulations"), acting under subregulation 16J(2) of the Regulations, designate Icatibant (FIRAZYR) as an orphan drug on 10 October 2013 for the treatment of angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema

The dose form of Icatibant (FIRAZYR) for this indication is solution for injection.

The sponsor of Icatibant (FIRAZYR) is Shire Australia Pty Ltd.

(Signed by)

Dr Anthony Gill Delegate of the Secretary

10 October 2013

PO Box 100 Woden ACT 2606 ABN 40 939 406 804

Phone: 02 6232 8444 Fax: 02 6203 1605 Email: info@tga.gov.au Website: http://www.tga.gov.au